Skip to Content

Incruse Ellipta Approval History

  • FDA approved: Yes (First approved April 30th, 2014)
  • Brand name: Incruse Ellipta
  • Generic name: umeclidinium
  • Dosage form: Inhalation Powder
  • Company: GlaxoSmithKline
  • Treatment for: COPD, Maintenance

Incruse Ellipta (umeclidinium) is an anticholinergic bronchodilator indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

Development History and FDA Approval Process for Incruse Ellipta

May  1, 2014Approval FDA Approves Incruse Ellipta (umeclidinium) for the Treatment of COPD

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.